CQDM – Quantum Leap Pharma-led Funding Program for Drug Discovery Research
Description:
CQDM’s Quantum Leap pharma-led funding program for drug discovery research helps SMEs or Canadian universities achieve innovative translational biopharmaceutical research projects. Projects selected as part of the Quantum Leap program focus on developing cutting-edge technologies with the potential to significantly advance the R&D activities of CQDM’s pharmaceutical members.
Comments on Funding:
Funding may consist in a grant or an investment.
Requested funds must range from $500,000 to $1,200,000. Exceptionally, CQDM may consider applications exceeding the maximum, if appropriate.
Applicants are responsible for raising matched funding for the project.
Eligibility:
Applicants must:
- be SMEs and public research institutions in Canada;
- conduct drug discovery research.
Applications Steps:
The applicant must:
Documentation Needed:
Applicants must submit the CVs of all involved researchers.
Other Things to Note:
- CQDM is a non-profit biopharmaceutical research consortium whose mission is to support and facilitate multi-stakeholder collaborative R&D that accelerates translation of leading-edge discoveries into vaccines, therapeutics and diagnostics addressing unmet medical needs while generating significant benefits for the Canadian economy.
- Call for proposals are open year-round for Quantum Leap projects. Deadline to participate in the next selection round: November 17th, 2022
Program Contact:
Quantum Leap Pharma-led Funding Program for Drug Discovery Research
When It Ends:
Ongoing
Deadline:
November 17, 2022
Next deadlines to be determined